) The objective of the Cell Line and Animal Testing Core Service D is to use state-of-the-art in vitro cell culture techniques and in vivo animal tumor models to successfully identify potential new anticancer agents from lead compounds produced by the NCDDG. The underlying hypothesis upon which work by the core service is based is that data obtained by in vitro screening with human tumor cell lines and in animal tumor models has predictive value for detennining which agents will be effective against cancers in humans.
The aims of the core service are: 1) to identify compounds having significant growth inhibitory activity against a panel of human tumor cell lines in culture; 2) to conduct in vivo testing of selected compounds using the hollow fiber assay in scid mice; 3) to conduct in vivo testing against early stage human tumor xenografts in scid mice; and, 4) to conduct in vivo testing and route and scheduling studies against advanced human tumor xenografts in scid mice. Selection criteria for advancing compounds through the testing process have been identified. The ultimate goal of the core service to identify from among the lead compounds and analogues synthesized by the NCDDG candidate drugs for preclinical development and eventual clinical trial as anticancer agents.
|Ihle, N T; Powis, G; Kopetz, S (2011) PI-3-Kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets 11:190-8|
|Liu, Enbo; Knutzen, Christine A; Krauss, Sybille et al. (2011) Control of mTORC1 signaling by the Opitz syndrome protein MID1. Proc Natl Acad Sci U S A 108:8680-5|
|Gwak, Ho-Shin; Shingu, Takashi; Chumbalkar, Vaibhav et al. (2011) Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128:787-96|
|Leone, Marilisa; Barile, Elisa; Vazquez, Jesus et al. (2010) NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH. Chem Biol Drug Des 76:10-6|
|Ihle, Nathan T; Powis, Garth (2010) The biological effects of isoform-specific PI3-kinase inhibition. Curr Opin Drug Discov Devel 13:41-9|
|Koul, Dimpy; Shen, Ruijun; Kim, Yong-Wan et al. (2010) Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12:559-69|
|Ihle, Nathan T; Powis, Garth (2010) Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 31:135-44|
|Gaitonde, Supriya; De, Surya K; Tcherpakov, Marianna et al. (2009) BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res 22:187-95|
|Ihle, Nathan T; Lemos, Robert; Schwartz, David et al. (2009) Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 8:94-100|
|Ihle, Nathan T; Lemos Jr, Robert; Wipf, Peter et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-50|
Showing the most recent 10 out of 34 publications